This specialized case study explores Kymanox’s approach to addressing heightened FDA reliability requirements for emergency-use autoinjectors through advanced Fault Tree Analysis and statistical testing strategies. Our team of SMEs collaborated closely with stakeholders to implement measurable improvements across system validation, regulatory compliance, and manufacturing quality assurance, achieving FDA approval and operational success.
CHALLENGE
SOLUTION
RESULTS
- A pharmaceutical organization faced new, stringent FDA reliability requirements for two (2) emergency-use Autoinjector (AI) products.
- Traditional statistical sampling and acceptance methods were insufficient to meet the FDA’s elevated standards.
- The FDA mandated a comprehensive Fault Tree Analysis (FTA) for system-wide risk assessment beyond conventional Failure Modes and Effects Analysis (FMEA) and manufacturing controls.
- Developed a novel strategy integrating advanced statistical sampling and created the Client’s first system-level FTA to validate overall product reliability.
- Provided statistical expertise to establish sampling and acceptance criteria balancing regulatory demands and practical manufacturing constraints.
- Designed and implemented a reliability demonstration method estimating false acceptance rates in 100% automated inspections, a critical FTA component.
- Collaborated closely with the Client’s Contract Manufacturing Organization (CMOs) and suppliers to ensure compliance with FDA reliability standards.
- Successfully secured FDA approval for two (2) reliability protocol reports, meeting the agency’s heightened regulatory requirements.
- Enabled the client to achieve the FDA’s strict reliability thresholds through innovative system-level risk analysis with FTA, setting a precedent for future validation.
- Enhanced the client’s capability to maintain compliance in a highly regulated medical devices market.